The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.
Biochem Biophys Res Commun. 2018 Jun 18;501(1):48-54. doi: 10.1016/j.bbrc.2018.04.129. Epub 2018 Apr 22.
Breast cancer is the most common cancer among women worldwide. Chemoresistance remains to be a considerable obstacle in breast cancer therapy and it is often involves dysregulation of a variety of microRNAs (miRNAs). miR-485-5p functions as a tumor suppressor in several types of human cancers. However, its role in breast cancer chemosensitivity have not been determined. In the present study, we demonstrated that overexpression of miR-485-5p suppresses breast cancer progression and enhances chemosensitivity both in vitro and in vivo. Further study demonstrated that miR-485-5p directly targeted the 3'-untranslated region of survivin and overexpression of survivin overcomes the miR-485-5p induced effects on breast cancer. In conclusion, our study identified that miR-485-5p suppresses cancer progression and enhances the chemosensitivity by targeting survivin. Targeting survivin by miR-485-5p may provide a potential approach to reverse chemosensitivity in breast cancer cells.
乳腺癌是全世界女性最常见的癌症。化疗耐药仍然是乳腺癌治疗的一个相当大的障碍，它通常涉及多种 microRNAs（miRNAs）的失调。miR-485-5p 在几种类型的人类癌症中作为肿瘤抑制因子发挥作用。然而，它在乳腺癌化疗敏感性中的作用尚未确定。在本研究中，我们证明了 miR-485-5p 的过表达抑制了体外和体内乳腺癌的进展并增强了化疗敏感性。进一步的研究表明，miR-485-5p 直接靶向生存素的 3'-非翻译区，而过表达生存素则克服了 miR-485-5p 对乳腺癌的诱导作用。总之，我们的研究表明，miR-485-5p 通过靶向生存素抑制癌症进展并增强化疗敏感性。通过 miR-485-5p 靶向生存素可能为逆转乳腺癌细胞的化疗耐药性提供一种潜在的方法。
